doi: 10.1016/S0140-6736(20)30925-9 2 World Health Organisation
Bimagrumab addresses a critical unmet need. Mark Pruzanski The advantage: While people on GLP-1 agonists tend to gain back any weight lost if they stop taking the meds, that might not be the case for bimagrumab 12 weeks after their last dose, the people in the 1,000-person phase 2 trial had yet to regain any weight
Given the potential for significant health improvements with semaglutide GLP-1 use, many find the investment worthwhile, as it may help in avoiding more expensive medical treatments in the future
Similarly, Gly-Leu-Pro, an ACE inhibitory peptide from chum salmon skin gelatin, exhibited an antihypertensive effect in spontaneously hypertensive rats, reducing systolic blood pressure by 31 mmHg after 6 h at a dosage of 20 mg/kg [141], suggesting that it could serve as a promising natural alternative for the development of functional foods aimed at controlling hypertension